<p>LifeMD（纳斯达克股票代码：LFMD - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$0.10），低于分析师一致预期的（$0.06），差距为（$0.04），据 Zacks 报道。LifeMD 更新了其 2025 财年的每股收益指引，并将 2025 年第四季度的每股收益指引进行了更新。</p>
<h2>LifeMD 股价上涨 2.2%</h2>
<ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
<p>周一，LifeMD 的股票在午盘交易中上涨了$0.10，达到了$4.73。该公司的股票交易量为 2,965,092 股，而其平均交易量为 1,506,321 股。该股票的 50 日移动平均为$6.07，200 日移动平均为$8.73。该公司的流动比率为 0.77，速动比率为 0.72，债务与股本比率为 9.21。该公司的市值为 2.243 亿美元，市盈率为-22.52，贝塔值为 1.57。LifeMD 的 1 年最低价为$4.13，1 年最高价为$15.84。</p>
<h2>LifeMD 内部交易活动</h2>
<p>在相关消息中，内部人士 Nicholas P. Alvarez 于 9 月 10 日（星期三）出售了 75,000 股该公司的股票。该股票以平均价格$5.92 出售，总交易额为$444,000.00。出售完成后，该内部人士直接持有 605,000 股公司股票，价值约为$3,581,600。这笔交易代表其持股减少了 11.03%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。18.40% 的股票目前由公司内部人士持有。</p>
<h2>机构投资者对 LifeMD 的看法</h2>
<ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
<p>一些机构投资者最近对该股票的持仓进行了调整。Tower Research Capital LLC TRC 在第二季度将其在 LifeMD 的持股增加了 110.4%。Tower Research Capital LLC TRC 现在拥有 4,674 股该公司的股票，价值$64,000，此前在上个季度又增持了 2,452 股。Quarry LP 在第三季度购买了 LifeMD 的新股份，价值约为$52,000。Legal &amp; General Group Plc 在第二季度将其在 LifeMD 的持股增加了 187.4%。Legal &amp; General Group Plc 现在拥有 10,144 股该公司的股票，价值$138,000，此前在上个季度又购买了 6,614 股。Hudson Bay Capital Management LP 在第二季度购买了 LifeMD 的新股份，价值$153,000。最后，纽约州共同退休基金在第二季度将其在 LifeMD 的持股增加了 2,180.0%。纽约州共同退休基金现在拥有 11,400 股该公司的股票，价值$155,000，此前在该期间又增持了 10,900 股。35.52% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>分析师的升级和降级</h2>
<p>几位分析师最近对 LFMD 股票发布了报告。华尔街 Zen 在 8 月 2 日（星期六）的一份研究报告中将 LifeMD 的股票评级从 “买入” 下调至 “持有”。Zacks Research 在 9 月 5 日（星期五）的一份研究报告中将 LifeMD 的评级从 “强烈卖出” 上调至 “持有”。KeyCorp 在 8 月 6 日（星期三）的一份研究报告中将 LifeMD 的目标价从$14.00 下调至$12.00，并对该股票给予 “增持” 评级。Lake Street Capital 在 8 月 6 日（星期三）的一份研究报告中将 LifeMD 的目标价从$18.00 下调至$14.00，并对该股票给予 “买入” 评级。最后，HC Wainwright 在 8 月 7 日（星期四）的一份研究报告中将 LifeMD 的目标价从$14.00 下调至$13.00，并对该公司给予 “买入” 评级。一位研究分析师对该股票给予了 “强烈买入” 评级，五位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为$13.17。</p>
<ul>
<li>LifeMD 可以凭借其 GLP-1 产品大幅上涨</li>
</ul>
<p><strong>获取我们对 LifeMD 的最新分析</strong></p>
<h2>LifeMD 公司简介</h2>
<p>（获取免费报告）</p>
<p>LifeMD, Inc 是一家直接面向患者的远程医疗公司，连接消费者与美国的医疗专业人员以提供医疗服务。该公司提供的远程医疗平台包括 RexMD，这是一个男性远程医疗品牌，为各种男性健康需求提供来自持牌医生的虚拟医疗治疗；ShapiroMD 提供虚拟医疗治疗、处方药、专利医生配方的非处方产品、外用复合药物和治疗男性和女性脱发的医疗设备；NavaMD 是一个女性导向的远程皮肤科，提供来自皮肤科医生和其他提供者的虚拟医疗治疗；以及处方口服和复合外用药物用于治疗衰老和痤疮；Cleared 提供个性化的过敏、哮喘和免疫治疗，包括环境和食物过敏的家庭测试、过敏和哮喘的处方以及治疗慢性过敏的免疫疗法。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 LifeMD 更好</li>
<li>消费品股票解析</li>
<li>D-Wave 与量子竞争对手在财报季后的比较</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>巴菲特减持苹果，退休前大举押注 Alphabet</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>三家能源巨头提高股息——这对投资者意味着什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 LifeMD 吗？</h2>
<p>在考虑 LifeMD 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 LifeMD 并不在名单上。</p>
<p>虽然 LifeMD 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LFMD

<p>LifeMD 报告的季度每股收益为（$0.10），比市场共识预期的（$0.06）低出$0.04。尽管盈利未达预期，股价仍上涨 2.2%，至$4.73。内部人士 Nicholas Alvarez 出售了 75,000 股，减少了 11.03% 的持股比例。机构投资者增加了持股，持有该股票的比例为 35.52%。分析师的评级意见不一，市场共识目标价为$13.17。LifeMD 在美国作为一家远程医疗公司运营</p>

<p>LifeMD (NASDAQ:LFMD - Get Free Report) issued its earnings results on Monday. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04), Zacks reports. LifeMD updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克股票代码：LFMD - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$0.10），低于分析师一致预期的（$0.06），差距为（$0.04），据 Zacks 报道。LifeMD 更新了其 2025 财年的每股收益指引，并将 2025 年第四季度的每股收益指引进行了更新。</p>
</div><h2>LifeMD Trading Up 2.2%</h2>
<div class="lb-trans"><h2>LifeMD 股价上涨 2.2%</h2>
</div><ul>
<li>Can the New CEO Revive This Struggling Telehealth Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
</div><p>LifeMD stock traded up $0.10 during mid-day trading on Monday, hitting $4.73. The company's stock had a trading volume of 2,965,092 shares, compared to its average volume of 1,506,321. The stock's fifty day moving average is $6.07 and its two-hundred day moving average is $8.73. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. The firm has a market capitalization of $224.30 million, a PE ratio of -22.52 and a beta of 1.57. LifeMD has a 1 year low of $4.13 and a 1 year high of $15.84.</p>
<div class="lb-trans"><p>周一，LifeMD 的股票在午盘交易中上涨了$0.10，达到了$4.73。该公司的股票交易量为 2,965,092 股，而其平均交易量为 1,506,321 股。该股票的 50 日移动平均为$6.07，200 日移动平均为$8.73。该公司的流动比率为 0.77，速动比率为 0.72，债务与股本比率为 9.21。该公司的市值为 2.243 亿美元，市盈率为-22.52，贝塔值为 1.57。LifeMD 的 1 年最低价为$4.13，1 年最高价为$15.84。</p>
</div><h2>Insider Activity at LifeMD</h2>
<div class="lb-trans"><h2>LifeMD 内部交易活动</h2>
</div><p>In related news, insider Nicholas P. Alvarez sold 75,000 shares of the firm's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the sale, the insider directly owned 605,000 shares of the company's stock, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 18.40% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Nicholas P. Alvarez 于 9 月 10 日（星期三）出售了 75,000 股该公司的股票。该股票以平均价格$5.92 出售，总交易额为$444,000.00。出售完成后，该内部人士直接持有 605,000 股公司股票，价值约为$3,581,600。这笔交易代表其持股减少了 11.03%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。18.40% 的股票目前由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On LifeMD</h2>
<div class="lb-trans"><h2>机构投资者对 LifeMD 的看法</h2>
</div><ul>
<li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. Quarry LP purchased a new stake in LifeMD in the third quarter valued at approximately $52,000. Legal &amp; General Group Plc lifted its stake in LifeMD by 187.4% during the second quarter. Legal &amp; General Group Plc now owns 10,144 shares of the company's stock worth $138,000 after purchasing an additional 6,614 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of LifeMD during the second quarter worth $153,000. Finally, New York State Common Retirement Fund boosted its holdings in LifeMD by 2,180.0% during the 2nd quarter. New York State Common Retirement Fund now owns 11,400 shares of the company's stock valued at $155,000 after acquiring an additional 10,900 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近对该股票的持仓进行了调整。Tower Research Capital LLC TRC 在第二季度将其在 LifeMD 的持股增加了 110.4%。Tower Research Capital LLC TRC 现在拥有 4,674 股该公司的股票，价值$64,000，此前在上个季度又增持了 2,452 股。Quarry LP 在第三季度购买了 LifeMD 的新股份，价值约为$52,000。Legal &amp; General Group Plc 在第二季度将其在 LifeMD 的持股增加了 187.4%。Legal &amp; General Group Plc 现在拥有 10,144 股该公司的股票，价值$138,000，此前在上个季度又购买了 6,614 股。Hudson Bay Capital Management LP 在第二季度购买了 LifeMD 的新股份，价值$153,000。最后，纽约州共同退休基金在第二季度将其在 LifeMD 的持股增加了 2,180.0%。纽约州共同退休基金现在拥有 11,400 股该公司的股票，价值$155,000，此前在该期间又增持了 10,900 股。35.52% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>Several analysts recently issued reports on LFMD shares. Wall Street Zen cut shares of LifeMD from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, August 2nd. Zacks Research upgraded LifeMD from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, September 5th. KeyCorp reduced their price objective on LifeMD from $14.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, August 6th. Lake Street Capital lowered their price objective on LifeMD from $18.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, August 6th. Finally, HC Wainwright cut their target price on LifeMD from $14.00 to $13.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $13.17.</p>
<div class="lb-trans"><p>几位分析师最近对 LFMD 股票发布了报告。华尔街 Zen 在 8 月 2 日（星期六）的一份研究报告中将 LifeMD 的股票评级从 “买入” 下调至 “持有”。Zacks Research 在 9 月 5 日（星期五）的一份研究报告中将 LifeMD 的评级从 “强烈卖出” 上调至 “持有”。KeyCorp 在 8 月 6 日（星期三）的一份研究报告中将 LifeMD 的目标价从$14.00 下调至$12.00，并对该股票给予 “增持” 评级。Lake Street Capital 在 8 月 6 日（星期三）的一份研究报告中将 LifeMD 的目标价从$18.00 下调至$14.00，并对该股票给予 “买入” 评级。最后，HC Wainwright 在 8 月 7 日（星期四）的一份研究报告中将 LifeMD 的目标价从$14.00 下调至$13.00，并对该公司给予 “买入” 评级。一位研究分析师对该股票给予了 “强烈买入” 评级，五位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为$13.17。</p>
</div><ul>
<li>LifeMD Can Surge on Its GLP-1 Offerings</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 可以凭借其 GLP-1 产品大幅上涨</li>
</ul>
</div><p><strong>Get Our Latest Analysis on LifeMD</strong></p>
<div class="lb-trans"><p><strong>获取我们对 LifeMD 的最新分析</strong></p>
</div><h2>LifeMD Company Profile</h2>
<div class="lb-trans"><h2>LifeMD 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.</p>
<div class="lb-trans"><p>LifeMD, Inc 是一家直接面向患者的远程医疗公司，连接消费者与美国的医疗专业人员以提供医疗服务。该公司提供的远程医疗平台包括 RexMD，这是一个男性远程医疗品牌，为各种男性健康需求提供来自持牌医生的虚拟医疗治疗；ShapiroMD 提供虚拟医疗治疗、处方药、专利医生配方的非处方产品、外用复合药物和治疗男性和女性脱发的医疗设备；NavaMD 是一个女性导向的远程皮肤科，提供来自皮肤科医生和其他提供者的虚拟医疗治疗；以及处方口服和复合外用药物用于治疗衰老和痤疮；Cleared 提供个性化的过敏、哮喘和免疫治疗，包括环境和食物过敏的家庭测试、过敏和哮喘的处方以及治疗慢性过敏的免疫疗法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than LifeMD</li>
<li>Consumer Staples Stocks, Explained</li>
<li>How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Buffett Trims Apple, Bets Big on Alphabet Ahead of Retirement</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 LifeMD 更好</li>
<li>消费品股票解析</li>
<li>D-Wave 与量子竞争对手在财报季后的比较</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>巴菲特减持苹果，退休前大举押注 Alphabet</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>三家能源巨头提高股息——这对投资者意味着什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LifeMD Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 LifeMD 吗？</h2>
</div><p>Before you consider LifeMD, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LifeMD 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 LifeMD 并不在名单上。</p>
</div><p>While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LifeMD 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LifeMD（NASDAQ:LFMD）发布了财报，每股收益比预期低 0.04 美元